The health consequences of using gadolinium have been controversial for years.

In January 2018, a Red Hand Letter was published because the European Medicines Agency (EMA) recommended that the approvals for intravenous linear gadolinium-containing contrast media in the EU be suspended, with the exception of the active ingredients gadoxetate acid and gadobenoic acid. the BfArM (Federal Institute for Drugs and Medical Devices) has endorsed this proposal and ordered the suspension of the approvals.

Dr. Eleonore Blaurock-Busch (Micro Trace Minerals GmbH) has carried out a current evaluation of the gadolinium and its chelation.

Attached is the english publication and its translation.